Literature DB >> 16091218

Advances in understanding immunologic control of HIV infection.

Stephen A Migueles1, John C Tilton, Mark Connors.   

Abstract

Over the past several years, the progress made in understanding the cellular immune response to HIV is likely greater compared to any other time since the beginning of the worldwide epidemic. This progress has largely been made possible by technical advances that have permitted a much more quantitative and highly detailed study of virus-specific cellular immunity in humans than was previously available. However, despite intensive study of the HIV-specific cellular immune response, we do not fully understand the nature of immunologic control in some rare cases and lack of control in most of untreated patients. It has become increasingly clear that HIV replication is poorly controlled in most untreated patients, despite a high-frequency HIV-specific cellular immune response. Therefore, attention has turned to qualitative features of the immune response that may dictate restriction of viral replication. Because most vaccines in preclinical or clinical testing rely on cellular immune responses that may alter disease progression but are unlikely to prevent infection, understanding these qualitative features is of particular importance. Further study could yield critical information for inducing effective immunity in vaccinees, preventing the loss of control of viral replication on the infection of vaccinees, or inducing immunologic control in infected humans.

Entities:  

Mesh:

Year:  2004        PMID: 16091218     DOI: 10.1007/s11904-004-0002-2

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  58 in total

1.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

Authors:  Christoph G Lange; Hernan Valdez; Kathy Medvik; Robert Asaad; Michael M Lederman
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

2.  Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.

Authors:  L Al-Harthi; J Siegel; J Spritzler; J Pottage; M Agnoli; A Landay
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

Review 3.  Human CD8(+) T-cell differentiation in response to viruses.

Authors:  René A W van Lier; Ineke J M ten Berge; Laila E Gamadia
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

4.  HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children.

Authors:  Zachary A Scott; Coreen M Beaumier; Mark Sharkey; Mario Stevenson; Katherine Luzuriaga
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

5.  Immunology. CD8 T cells remember with a little help.

Authors:  Susan M Kaech; Rafi Ahmed
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

6.  High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

Authors:  A C McNeil; W L Shupert; C A Iyasere; C W Hallahan; J A Mican; R T Davey; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

7.  Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation.

Authors:  L A Trimble; P Shankar; M Patterson; J P Daily; J Lieberman
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 8.  Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection.

Authors:  J Lieberman; P Shankar; N Manjunath; J Andersson
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

9.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

Authors:  N L Haigwood; A Watson; W F Sutton; J McClure; A Lewis; J Ranchalis; B Travis; G Voss; N L Letvin; S L Hu; V M Hirsch; P R Johnson
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

10.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more
  7 in total

Review 1.  Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control.

Authors:  Adam R Hersperger; Stephen A Migueles; Michael R Betts; Mark Connors
Journal:  Curr Opin HIV AIDS       Date:  2011-05       Impact factor: 4.283

2.  Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness.

Authors:  Prasanna Jagannathan; Christine M Osborne; Cassandra Royce; Maura M Manion; John C Tilton; Li Li; Steven Fischer; Claire W Hallahan; Julia A Metcalf; Mary McLaughlin; Matthew Pipeling; John F McDyer; Thomas J Manley; Jeffery L Meier; John D Altman; Laura Hertel; Richard T Davey; Mark Connors; Stephen A Migueles
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

3.  Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.

Authors:  Stephen A Migueles; Christine M Osborne; Cassandra Royce; Alex A Compton; Rohan P Joshi; Kristin A Weeks; Julia E Rood; Amy M Berkley; Jonah B Sacha; Nancy A Cogliano-Shutta; Margaret Lloyd; Gregg Roby; Richard Kwan; Mary McLaughlin; Sara Stallings; Catherine Rehm; Marie A O'Shea; JoAnn Mican; Beverly Z Packard; Akira Komoriya; Sarah Palmer; Ann P Wiegand; Frank Maldarelli; John M Coffin; John W Mellors; Claire W Hallahan; Dean A Follman; Mark Connors
Journal:  Immunity       Date:  2008-12-08       Impact factor: 31.745

4.  Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Authors:  Stephen A Migueles; Kristin A Weeks; Eric Nou; Amy M Berkley; Julia E Rood; Christine M Osborne; Claire W Hallahan; Nancy A Cogliano-Shutta; Julia A Metcalf; Mary McLaughlin; Richard Kwan; JoAnn M Mican; Richard T Davey; Mark Connors
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

5.  Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  AIDS Res Treat       Date:  2012-05-27

6.  Bispecific antibody-derived molecules to target persistent HIV infection.

Authors:  Jeffrey L Nordstrom; Guido Ferrari; David M Margolis
Journal:  J Virus Erad       Date:  2022-08-28

7.  Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure.

Authors:  Haishan Li; Tyler Lahusen; Lingzhi Xiao; Nidal Muvarak; Jana Blazkova; Tae-Wook Chun; C David Pauza
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-03       Impact factor: 6.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.